|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 09-01 | Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target | MT |
| 08-06 | Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib | DJ |
Main competitors
| Dividend Yield (N) | Dividend Yield (N+1) | P/E (N) | Price to Book (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 1.42% | 1.56% | 20.87x | 4.92x | 7.45x | 14.96x | 16.92x | 71.53B | ||
| 0.04% | 0.08% | 31.24x | 6.16x | 9x | 28.05x | 28.57x | 60.12B | ||
| 0.95% | 1.1% | 34.13x | 4.56x | 6.11x | 18.31x | 25.62x | 48.85B | ||
| -.--% | -.--% | 34.64x | 6.44x | 3.34x | 14.41x | 21.25x | 44.28B | ||
| -.--% | -.--% | -21.08x | 22.16x | 228.26x | -22.72x | -21.59x | 43.83B | ||
| -.--% | -.--% | 47.85x | 8.1x | 5.53x | 30.37x | 34.94x | 41.53B | ||
| 0.42% | 0.44% | 27.07x | 2.2x | 7.8x | 20.09x | 23.54x | 30.13B | ||
| -.--% | -.--% | 32.39x | 3.4x | 6.91x | 17.94x | 21.51x | 27.98B | ||
| -.--% | -.--% | -70.94x | 35.75x | 13.62x | -69.42x | -78.99x | 25.25B | ||
| -.--% | -.--% | -15.26x | 1.25x | 5.8x | -7.29x | -5.75x | 24.76B | ||
| -.--% | -.--% | 28.97x | 3.45x | 5.43x | 18.06x | 20.37x | 20.99B | ||
| -.--% | -.--% | 35.38x | 26.37x | 5.81x | 26.42x | 27.64x | 17.36B | ||
| 0.33% | 0.2% | 44.22x | 10.83x | 16.41x | 33.73x | 36.24x | 15.54B | ||
| 1.05% | 1.19% | 25.4x | 2.82x | 2.2x | 9.49x | 14.72x | 14.99B | ||
| -.--% | -.--% | -59.3x | 29.72x | 9.71x | 237.07x | -1802.76x | 14.9B | ||
| -.--% | -.--% | 18.11x | 5.58x | 5.4x | 12.61x | 13.37x | 14.53B | ||
| -.--% | -.--% | 1028.84x | 16.69x | 35.99x | 621.71x | -232.89x | 14.41B | ||
| -.--% | -.--% | 78.65x | 4.72x | 4.16x | 15.97x | 19.82x | 14.13B | ||
| Average | 0.23% | 0.25% | 73.40x | 10.84x | 21.05x | 56.65x | -102.08x | 30.28B | |
| Weighted average by Cap. | 0.34% | 0.37% | 45.48x | 9.55x | 25.63x | 33.26x | -42.66x |
- Stock Market
- Stocks
- ACRS Stock
- Stock
- Sector ACLS THER
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
















